SCTbio vs WuXi Biologics: CDMO Comparison

How does SCTbio compare to WuXi Biologics?

As of Jul 2026, SCTbio: no FDA inspections on file, 5 EMA/MHRA GMP certificates. Signal Score 81.6. WuXi Biologics: 1 FDA inspection (including 0 NAI, 1 VAI and 0 OAI), 4 EMA/MHRA GMP certificates. Signal Score 82.7. Counts are the established FDA, EMA and MHRA records on each profile. CDMOs cannot pay to change a score.

Side-by-side comparison of SCTbio and WuXi Biologics on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

SCTbio → 81.6
Prague, Czech Republic
Signal Score
82/100
Quality (FDA + GMP)
100/100
FDA inspections
0
FDA warning letters
0
EMA GMP certificates (active)
5
MHRA GMP certificates (compliant)
0
Clinical programs (matched)
0
Capacity
—
Modalities
CAR-T, Cell Therapy
Shanghai, CN · Wuxi, CN
Signal Score
83/100
Quality (FDA + GMP)
100/100
FDA inspections
1
— NAI / VAI / OAI
0 / 1 / 0
FDA warning letters
0
EMA GMP certificates (active)
3
MHRA GMP certificates (compliant)
1
Clinical programs (matched)
0
Capacity
—
Modalities
CAR-T, Cell Therapy, AAV, ADC, Monoclonal Antibody

Key differences

  • WuXi Biologics has FDA inspections on record (1); SCTbio does not yet appear in the FDA inspection database.
  • Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
  • WuXi Biologics maintains 1 MHRA / UK GMP certificate; SCTbio does not.

Across the cross-modality scorecard, WuXi Biologics carries the higher composite Signal Score — but the right choice depends on the specific modality, phase, and geography of the program.

Frequently asked: SCTbio vs WuXi Biologics

How does SCTbio compare to WuXi Biologics?

On CDMO Signal's composite Signal Score, SCTbio is 82/100 and WuXi Biologics is 83/100; SCTbio has 0 FDA inspections on record vs 1 for WuXi Biologics; European coverage is 5 active EMA+MHRA certificates for SCTbio vs 4 for WuXi Biologics. Both are tracked in the CDMO Signal directory. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.

Which has the stronger FDA inspection record, SCTbio or WuXi Biologics?

Both SCTbio and WuXi Biologics maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. SCTbio has 0 FDA inspections on record; WuXi Biologics has 1.

How do SCTbio and WuXi Biologics compare on European GMP coverage?

SCTbio holds 5 active EMA GMP certificates and 0 MHRA / UK certificates. WuXi Biologics holds 3 active EMA GMP certificates and 1 MHRA / UK certificate. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.

What does the Signal Score gap mean in practice?

SCTbio carries a Signal Score of 82/100 and WuXi Biologics carries 83/100 — essentially tied for WuXi Biologics. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.

Evaluating SCTbio and WuXi Biologics for a program?

Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.

Find & compare CDMOs →
Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.